ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 176 filers reported holding ASCENDIS PHARMA A/S in Q4 2020. The put-call ratio across all filers is 1.39 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $2,200,000 | -50.6% | 18,743 | -43.4% | 0.00% | -50.0% |
| Q4 2021 | $4,453,000 | +1.3% | 33,100 | +20.0% | 0.00% | 0.0% |
| Q3 2021 | $4,398,000 | +21.3% | 27,591 | +0.1% | 0.00% | 0.0% |
| Q2 2021 | $3,626,000 | +41.0% | 27,565 | +38.2% | 0.00% | +100.0% |
| Q1 2021 | $2,571,000 | -19.7% | 19,945 | +3.9% | 0.00% | -50.0% |
| Q4 2020 | $3,200,000 | +105.7% | 19,189 | +90.3% | 0.00% | +100.0% |
| Q3 2020 | $1,556,000 | +13.4% | 10,082 | +8.7% | 0.00% | 0.0% |
| Q2 2020 | $1,372,000 | +73.9% | 9,275 | +32.4% | 0.00% | 0.0% |
| Q1 2020 | $789,000 | +110.4% | 7,005 | +160.0% | 0.00% | – |
| Q4 2019 | $375,000 | -32.4% | 2,694 | -53.2% | 0.00% | – |
| Q3 2019 | $555,000 | +32.5% | 5,758 | +58.4% | 0.00% | – |
| Q2 2019 | $419,000 | +48.1% | 3,636 | +51.3% | 0.00% | – |
| Q1 2019 | $283,000 | +32.9% | 2,403 | -29.4% | 0.00% | – |
| Q4 2018 | $213,000 | – | 3,402 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |